Trial Profile
Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2019
Price :
$35
*
At a glance
- Drugs Orvepitant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms VOLCANO-1
- Sponsors NeRRe Therapeutics
- 14 Aug 2019 Results published in the Chest
- 24 May 2017 Primary endpoint (change in objective daytime cough frequency at Week 4 compared to Baseline) has been met, as per the results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society